- Home
- HUBS vs MRNA Comparison
HUBS vs MRNA Comparison
Compare HUBS & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HUBS | MRNA |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5B | 19.7B |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HUBS | MRNA |
|---|---|---|
| Price | $191.89 | $50.81 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 32 | 12 |
| Target Price | ★ $445.66 | $34.27 |
| AVG Volume (30 Days) | 1.2M | ★ 5.3M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 855.56 | 21.77 |
| EPS | ★ 0.86 | N/A |
| Revenue | $375,612,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $20.46 | $8.74 |
| Revenue Next Year | $16.01 | $16.18 |
| P/E Ratio | $239.42 | ★ N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $198.51 | $22.28 |
| 52 Week High | $670.54 | $59.55 |
Technical Indicators
Market Signals| Indicator | HUBS | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 26.12 | 50.91 |
| Support Level | N/A | $47.61 |
| Resistance Level | $256.65 | $54.94 |
| Average True Range (ATR) | 15.13 | 2.53 |
| MACD | -4.61 | -0.21 |
| Stochastic Oscillator | 5.61 | 50.66 |
Price Performance
Historical ComparisonAbout HUBS HubSpot Inc.
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.